Protease-activatable fc domain binding molecules

By binding molecules to the Fc domain, which is activated by proteases, and utilizing the protease cleavage linker to cleave the masked portion near tumor cells, specific binding to tumor antigens is achieved. This solves the problems of downregulation of tumor cell antigens and the presence of antigens in healthy tissues in existing technologies, thus improving the safety and efficacy of cancer immunotherapy.

CN122422352APending Publication Date: 2026-07-17F HOFFMANN LA ROCHE & CO AG
View PDF 29 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
F HOFFMANN LA ROCHE & CO AG
Filing Date
2024-12-09
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing innate immune cell binders can lead to target detumescence when faced with downregulation of tumor cell antigens and the presence of antigens of interest in healthy tissues, making it difficult to achieve effective cancer immunotherapy.

Method used

A protease-activated Fc domain binding molecule was designed to achieve specific binding to tumor antigens by cleaving the masked portion of the protease cleavage linker near the target cell, thereby exposing the masked portion. The molecule also recruits innate cells through the Fc domain to perform ADCC and/or ADCP.

Benefits of technology

It improves tumor specificity, reduces antigen escape, decreases toxicity to healthy tissues, and enhances the safety and efficacy of cancer immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

本发明总体上涉及新型蛋白酶可活化的 Fc 结构域结合分子、编码此类分子的多核苷酸，以及包含此类多核苷酸的载体和宿主细胞。本发明进一步涉及用于产生本发明的分子的方法，并且涉及使用这些分子治疗疾病的方法。
Need to check novelty before this filing date? Find Prior Art